BPMC
|Blueprint Medicines Corp
NASDAQ
USD 127.90
-0.20|-0.16%
Current Price
USD 127.90
Change
USD -0.20 (-0.16%)
P/E Ratio
Dividend Yield
Market Cap
6.15B
Volume
4.44M
Open
USD 128.10
Previous Close
USD 128.10
52-Week High
USD 121.90
52-Week Low
USD 73.04
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell...
Sector:Healthcare
Industry:Biotechnology
CEO:Ms. Kathryn Haviland M.B.A.
Employees:682
Headquarters:Cambridge, USA
Website:www.blueprintmedicines.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions